




Figure S1. The cost-effectiveness acceptability curve.The red curve indicated the probability of pembrolizumab plus EP being cost-effective against placebo plus EP under different pembrolizumab price/mg at the WTP thresholds of $100,000 per QALY. QALY indicated quality-adjusted life-year; EP, etoposide-platinum.




(a)



(b)



(c)



(d)

Figure S2. Parametric survival distributions fitted and extrapolated. (a)OS data fitted and extrapolated for pembrolizumab plus EP; (b)OS data fitted and extrapolated for placebo plus EP; (c)PFS data fitted and extrapolated for pembrolizumab plus EP; (d)PFS data fitted and extrapolated for placebo plus EP.